DDInter1224 DDInter1435
Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines. Minocycline was granted FDA approval on 30 June 1971.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Minocycline {u} (Compound) resembles {v} (Compound) Demeclocycline
Minocycline {u} (Compound) resembles {v} (Compound) Oxytetracycline
Minocycline {u} (Compound) binds {v} (Gene) ALOX5
Minocycline {u} (Compound) is included by {v} (Pharmacologic Class) Tetracyclines
Minocycline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Indapamide
Minocycline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Trichlormethiazide
Minocycline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin glulisine
Minocycline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nafcillin
Minocycline {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Minocycline {u} may lead to a major life threatening interaction when taken with {v} Acitretin
Minocycline (Compound) resembles Demeclocycline (Compound)
Minocycline (Compound) resembles Oxytetracycline (Compound)
Minocycline (Compound) binds ALOX5 (Gene)
Minocycline (Compound) is included by Tetracyclines (Pharmacologic Class)
Minocycline may cause a minor interaction that can limit clinical effects when taken with Indapamide
Minocycline may cause a minor interaction that can limit clinical effects when taken with Trichlormethiazide
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin
Minocycline may lead to a major life threatening interaction when taken with Lomitapide
Minocycline may lead to a major life threatening interaction when taken with Acitretin